Nasdaq:LYEL
Lyell Immunopharma, Inc.
A clinical-stage biopharma developer of TIGIT checkpoint inhibitors for oncology with a current market cap driven by future potential rather than historical earnings.
Key Metrics
Investment Thesis
Bull Case
Investors may buy this stock anticipating a successful Phase 3 trial readout for the TIGIT antibody which could trigger a massive valuation re-rating upon partnership announcements or regulatory approval. The current low asset base offers significant downside protection while providing high optionality value if the clinical data proves superior to existing checkpoint inhibitors. Any strategic deal with a major pharma partner would likely provide immediate capital relief and validate the technology platform.
Bear Case
The company faces an imminent liquidity crisis with cash reserves of only $105.6M against annualized burn rates that suggest less than two years of runway without external funding. Historical data shows a consistent decline in profitability and negligible revenue growth, indicating high failure risk for the primary asset. High dilution risks from future equity raises could severely damage existing shareholder value if no strategic partner is found before cash runs out.
About Lyell Immunopharma, Inc.
Lyell Immunopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies primarily for the oncology market. The company focuses on its proprietary TIGIT inhibitor, LY3300359, which targets immune checkpoints to enhance anti-tumor immunity. With minimal recent revenue and significant cash burn, the firm relies heavily on capital markets and potential strategic partnerships to fund its high-risk R&D pipeline.
Analysis
Management Discussion
The company reported a net loss of $343.0M in 2024, continuing a trend of widening losses from -$183.1M in 2022 to -$234.6M in 2023, driven by high operating expenses of $358.8M and minimal revenue of only $61,000. Despite holding over $105M in cash equivalents and marketable securities, the negative cash flow from operations indicates that current spending on research and development significantly outpaces any generated income, raising concerns about runway sustainability.
Industry Overview
The oncology immunotherapy sector is highly competitive with established players like Merck and Bristol Myers Squibb dominating the market, making it difficult for clinical-stage companies to achieve commercial success without significant differentiation. Regulatory pathways for checkpoint inhibitors are well-defined but expensive, requiring substantial capital investment before any revenue generation occurs. Market consolidation is increasing, favoring large pharma acquisitions over independent biotech survival.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $84.7M | $130.0K | $61.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $84.7M | $130.0K | $61.0K |
| Operating Expenses | $271.7M | $247.1M | $358.8M |
| Operating Income | $-187.1M | $-247.0M | $-358.8M |
| R&D | $159.2M | $182.9M | — |
| G&A | $117.3M | $67.0M | $52.0M |
| Stock-Based Comp | $81.9M | $47.1M | $33.1M |
| D&A | $18.0M | $20.2M | $19.6M |
| Depreciation | $18.0M | $20.2M | $19.4M |
| Other OpEx | $-4.8M | $-2.8M | $306.8M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-187.1M | $-247.0M | $-358.8M |
| Income Tax | $-3.9M | $-12.4M | $-15.8M |
| Continuing Ops | $-183.1M | $-234.6M | $-343.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-183.1M | $-234.6M | $-343.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-183.1M | $-234.6M | $-343.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $651.3M | $554.7M | $379.6M |
| Cash & Equivalents | $123.6M | $145.6M | $105.6M |
| Marketable Securities | $516.6M | $400.6M | $264.9M |
| Prepaid Expenses | $11.1M | $8.5M | $9.1M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $286.3M | $195.3M | $111.3M |
| PP&E (Net) | $123.0M | $102.7M | $48.2M |
| Operating Leases | $43.2M | $39.7M | $24.7M |
| LT Securities | $70.1M | $16.5M | $13.0M |
| Other LT Assets | $49.9M | $36.5M | $25.3M |
| Total Assets | $937.6M | $750.0M | $490.9M |
| Current Liabilities | $37.0M | $34.5M | $53.8M |
| Accounts Payable | $3.9M | $4.8M | $5.4M |
| Current Leases | $4.5M | $6.3M | $8.0M |
| Deferred Revenue | $0 | — | — |
| Other Current Liab | $28.6M | $23.4M | $40.4M |
| Long-Term Liabilities | $67.3M | $60.6M | $54.2M |
| LT Operating Leases | $63.2M | $56.9M | $51.0M |
| Other LT Liab | $4.1M | $3.7M | $3.3M |
| Total Liabilities | $104.3M | $95.1M | $108.0M |
| Shareholders' Equity | $833.3M | $655.0M | $382.8M |
| Paid-In Capital | $1.61B | $1.66B | $1.73B |
| Retained Earnings | $-767.5M | $-1.00B | $-1.35B |
| AOCI | $-7.6M | $-94.0K | $291.0K |
| Total L&E | $937.6M | $750.0M | $490.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-183.1M | $-234.6M | $-343.0M |
| Non-Cash Adjustments | $91.6M | $73.8M | $187.3M |
| Working Capital Changes | $-78.1M | $-2.8M | $-6.7M |
| Cash from Operations | $-169.6M | $-163.7M | $-162.4M |
| Capital Expenditures | $24.3M | $2.7M | $464.0K |
| Cash from Investing | $-11.5M | $184.0M | $122.4M |
| Share Buybacks | $0 | — | — |
| Cash from Financing | $10.6M | $1.7M | $1.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-170.5M | $22.1M | $-38.6M |
| Beginning Cash | $294.3M | $123.8M | $145.9M |
| Ending Cash | $123.8M | $145.9M | $107.3M |
Frequently Asked Questions
How does Lyell Immunopharma, Inc. make money?
Oncology Immunotherapy (primary focus on the TIGIT antibody candidate), Strategic Licensing and Collaboration Partnerships, and Pre-commercial R&D Operations which currently absorb all operating expenses due to lack of commercial product revenue.
What are the main risks for LYEL?
Prolonged cash burn rate of $343M net loss threatening liquidity given the limited remaining cash balance of approximately $107M, potential failure to secure a successful pivotal trial readout or strategic partnership deal, and regulatory hurdles associated with bringing novel immunotherapies to market.
What is LYEL's competitive advantage?
First-in-class or best-in-class potential of the LY3300359 anti-TIGIT antibody mechanism, a robust intellectual property portfolio protecting its core platform, and an experienced management team with deep expertise in oncology immunotherapy development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.